גאלאפולד 123 מג ישראל - עברית - Ministry of Health

גאלאפולד 123 מג

truemed ltd, israel - migalastat as hydrochloride - קפסולה קשיחה - migalastat as hydrochloride 123 mg

זבסקה ישראל - עברית - Ministry of Health

זבסקה

j-c health care ltd - miglustat - קפסולות - miglustat 100 mg - miglustat - miglustat - zavesca is indicated for the oral treatment of mild to moderate type i gaucher disease. zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.

סרדלגה ישראל - עברית - Ministry of Health

סרדלגה

sanofi israel ltd - eliglustat - קפסולה קשיחה - eliglustat 84.4 mg - eliglustat

מיגלוסטאט דיפארמה ישראל - עברית - Ministry of Health

מיגלוסטאט דיפארמה

mbi pharma ltd., israel - miglustat - קפסולה קשיחה - miglustat 100 mg - miglustat

מיגלוסטט ג'י.אל. 100 מג ישראל - עברית - Ministry of Health

מיגלוסטט ג'י.אל. 100 מג

a.l. medi-market ltd. - miglustat - קפסולות - miglustat 100 mg - miglustat

אגרסטט ישראל - עברית - Ministry of Health

אגרסטט

tzamal bio-pharma ltd - tirofiban as hydrochloride monohydrate - תמיסה לאינפוזיה - tirofiban as hydrochloride monohydrate 0.05 mg/ml - tirofiban - tirofiban - aggrastat in combination with heparin, is indicated for patients with unstable angina or non-q-wave myocardial infarction to prevent cardiac ischemic events and is also indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing ptca or atherectomy. in this setting, aggrastat has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure.

אגרסטט ישראל - עברית - Ministry of Health

אגרסטט

tzamal bio-pharma ltd - tirofiban as hydrochloride monohydrate 0.25 mg/ml - solution for infusion - tirofiban - aggrastat in combination with heparin, is indicated for patients with unstable angina or non-q-wave myocardial infarction to prevent cardiac ischemic events and is also indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing ptca or atherectomy. in this setting, aggrastat has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure.

טריכלונם אלקסיר ישראל - עברית - Ministry of Health

טריכלונם אלקסיר

cts chemical industries ltd, israel - triclofos sodium - תמיסה אלכוהולית - triclofos sodium 500 mg / 5 ml - triclofos - triclofos - insomnia, daytime sedation and pre-medication in eec.